Mark Foletta Sells 2,000 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 2,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the completion of the transaction, the director directly owned 48,852 shares in the company, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 4.9%

NASDAQ DXCM opened at $82.66 on Thursday. The stock has a market capitalization of $31.19 billion, a P/E ratio of 32.67, a P/E/G ratio of 1.45 and a beta of 1.41. The business has a 50 day simple moving average of $73.99 and a 200 day simple moving average of $69.53. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a one year low of $54.11 and a one year high of $87.85.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.48 earnings per share. Research analysts expect that DexCom, Inc. will post 2.65 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on DXCM. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Stifel Nicolaus set a $95.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Monday. Wells Fargo & Company raised their target price on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, UBS Group set a $96.00 target price on DexCom and gave the company a “buy” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DXCM. Reflection Asset Management bought a new stake in shares of DexCom during the fourth quarter worth about $25,000. Ascentis Independent Advisors acquired a new stake in shares of DexCom in the 1st quarter worth about $25,000. MCF Advisors LLC bought a new position in DexCom in the 4th quarter valued at about $32,000. Wellington Grp LLC boosted its stake in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new position in DexCom during the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.